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Expression
Activation
RegulationNitric oxide (NO) and matrix metalloproteinase 9 (MMP-9) levels are found to increase in inﬂammation
states and in cancer, and their levels may be reciprocally modulated. Understanding interactions between NO
andMMP-9 is of biological and pharmacological relevance andmay prove crucial in designing new therapeutics.
The reciprocal interaction between NO and MMP-9 have been studied for nearly twenty years but to our
knowledge, are yet to be the subject of a review. This review provides a summary of published data regarding
the complex and sometimes contradictory effects of NO on MMP-9. We also analyse molecular mechanisms
modulating and mediating NO-MMP-9 interactions. Finally, a potential therapeutic relevance of these
interactions is presented.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
1.1. Matrix metalloproteinases
Matrix metalloproteinases (MMPs) are a group of structurally simi-
lar endopeptidases with a zinc ion in the active site. All are capable of
digesting components of the extracellular matrix including collagens,
laminins, ﬁbronectin, elastin, and proteoglycans. MMPs play a key role
in controlling homeostasis of all extracellular matrix (ECM) proteins.
The MMPs regulate cell function, growth and division, host defences,
ECM synthesis, morphogenesis, wound healing, tissue repair, skeletal
formation, apoptosis, as well as cleavage of transmembrane proteins
and bioactive molecules. Dysregulation of theMMPs has been implicat-
ed in tumour angiogenesis, invasion and metastasis, inﬂammatory
bowel disease, arthritis, atherosclerosis, respiratory and heart disease
and may also play other diverse pathological roles [1–6].
1.1.1. Matrix metalloproteinase-9 and cardiovascular disease
OfMMPs,MMP-9 can be upregulated and it has been implicated in a
variety of pathological conditions. A selective inhibition of MMP-9 may
have a signiﬁcant therapeutic relevance for the treatment of various
inﬂammatory diseases. Cardiovascular (CV) disease, diabetes andharmaceutical Sciences, Trinity
ights reserved.cancer are responsible for the majority of human deaths in the devel-
oped world and have all been associated with MMP-9 abnormalities.
For example, changes in the CV extracellular matrix (ECM) are regulat-
ed by the gelatinases and their tissue inhibitors and, as key components
of CV remodelling, are associated with inﬂammation and reactive,
rather than reparative, ﬁbrosis [7,8]. MMP-2 and MMP-9 knockout
models are associated with reduced aortic elastin degradation [9] and
protection from pressure overload myocardial hypertrophy, ﬁbrosis
and dysfunction [10]. Post-infarctionmodels andmodels of left ventric-
ular arrythmogenesis have shown that MMP-9 gene promoters are
temporally activated speciﬁcally in the region of myocardial injury
[11,12]. The genepromoter region ofMMP-9 includes a proximal activa-
tor protein-1 (AP-1) site which mediates an enhanced transcriptional
response to a wide variety of cytokine and cellular stimuli [13]. In the
clinic, independent associations between myocardial remodelling
post-MI, left ventricular dysfunction and heart failure, have been identi-
ﬁed with markers of inﬂammation, ﬁbrosis and MMP-9 [8,14–17].
1.1.2. Matrix metalloproteinase-9 and diabetes
Microvascular and macrovascular complications of diabetes are
associatedwithMMP-9 dysregulation. In an animalmodel of diabetic ret-
inopathy, increased MMP-9 activity was observed in retinal microvessels
andMMP-9 knockoutwas protective [18]. In patients, increased urinary
excretion ofMMP-9 supports a role forMMP-9 dysregulation in diabetic
renal dysfunction [19] and aortic and coronary arteries of diabetic
patients taken at autopsy had higher expression of MMP-9 compared
604 S. O'Sullivan et al. / Biochimica et Biophysica Acta 1843 (2014) 603–617to non-diabetics and were correlated with HbA1c as well as apoptosis
[20]. Elevated MMP-9 has also been associated with arterial stiffness
in patients with diabetes [21]. Furthermore, human genetic polymor-
phisms associatedwithMMP-9 elevation support a role for this enzyme
in the pathophysiology of vascular disease. The 1562C N T single
neucleotide polymorphism (SNP), which affects the promoter region
ofMMP-9 gene and increases circulating levels ofMMP-9, is signiﬁcant-
ly associated with vascular disease in type 2 diabetes mellitus [22]. In
age and sex matched controls, patients with type 2 diabetes, without
and with microangiopathy, T allele frequencies were 11.9%, 13.1% and
24.4% respectively (p b 0.05).
1.1.3. Matrix metalloproteinase-9 and cancer
Matrix metalloproteinases (MMPs) play a central role in cancer
cell intravasation and extravasation and their plasma levels are known
biomarkers of breast, ovarian, colorectal, renal, pancreas, bladder and
lung cancers [23]. MMP-9, in particular, regulates vascular endothelial
growth factors, which, in turn, promote tumour growth and angiogene-
sis [24]. MMP-9 also modulates tumour-associated inﬂammation via
cytokines and their receptors [25] and is involved in endothelial–
mesenchymal-transition (EMT) whereby cells acquire migratory
characteristics [26]. While, numerous preclinical studies demonstrate
the ability of MMP inhibitors to delay primary tumour growth and
block metastasis [27], MMP inhibition in the clinic has been limited by
toxicity, including dose-limiting musculoskeletal pain and inﬂamma-
tion [28], while recent research on the development of MMP inhibitors
has been focused on selective inhibition of MMPs [29].
1.1.4. Matrix metalloproteinase-9 and other diseases
MMP-9 abnormalities have been associated with disease progres-
sion in many other key organs. In the liver, MMP-9 has been associated
with the ﬁbrotic response to hepatitis C [30] and inmodels of fulminant
liver failure whereMMP-9 expression is increased, inhibition of MMP-9
was associated with improvement outcome when used early in the
natural history of the disease [31]. In patientswith kidney disease, inter-
stitial ﬁbrosis correlatedwithMMP-9 expression in the atrophic tubular
nuclei [32] and elevated MMP-9 is also associated with the vascular
complications of chronic kidney disease associated with diabetes [33].
In children with aggressive chronic renal dysfunction, focal segmental
glomeruloscloerosis is associated with elevated MMP-9, which may
represent an early diagnostic biomarker as well as a therapeutic target
[21]. In the gastrointestinal tract, elevated expression of MMP-9 is
a feature of inﬂammatory bowel diseases such as Crohn's disease
[34–36] and MMP-9 expressed in epithelial colonic tissue mediates in-
ﬂammation in colitis with simultaneous increase in proinﬂammatory
mediators [37].
The above paragraphs highlight the need for an MMP-9 inhibitor;
however, to date, clinical trials of MMP inhibitors have been largely
unsuccessful. Misguided outcome expectations combined with poor
fundamental understanding of the complex role of MMPs in cancer
and inﬂammation are seen as the main contributors to these failures.
Several excellent reviews have examined the outcomes and postulate
that a greater understanding of the role of MMPs in a given disease
setting may yet offer hope for a clinically relevant MMP inhibitor in
the future [1,38,39]. Improved selectivity for MMP-9 over constitutive
MMPs would certainly be of beneﬁt [40] and also an ability to target
the dysregulation of the enzyme that leads to its pathophysiological
role. Understanding the interactions of NO and MMP-9 may offer
insights into novel mechanisms to inhibit the enzyme in disease states.
1.1.5. Structure and regulation of MMP-9
MMP-9 and MMP-2 are classiﬁed as gelatinases, owing to their
ability to process synthetic gelatine. This designationmay be considered
a little arbitrary as they can digest a variety of the matrix proteins and
have ability to cleave a growing list of bioactive molecules including
transmembrane proteins [41]. Structurally, MMP-9 is composed ofseveral domains, including the pre, pro, and catalytic domains which
connect to the C-terminal hemopexin-like domain via a hinge or linker
region [42]. The hemopexin domain not only acts as a stubstrate binding
domain [43] but can also interact with integrins on the cell surface to
anchor MMP-9 and has been shown to trigger anti-apoptotic signalling
pathways in B-cell chronic lymphocytic leukaemia [44]. All MMPs
possess a catalytic domain of 165–170 amino acids which is essential
for proteolysis [42,45]. The catalytic domain varies slightly in groove
depth and the accessibility and depth of six side pockets that ﬂank the
deﬁning zinc ion which is coordinated at the centre of the cleft by
three histidine residues [46]. The S1′ pocket has the greatest variation
amongst the MMPs in both depth and amino acid composition. These
features have made it an attractive target for small molecule inhibitor
development. The gelatinases also have three ﬁbronectin-like inserts
in the catalytic domain and these differences account, in part for their
differing substrate speciﬁcities [47,48].
MMP-9 is principally regulated at the level of transcription by vari-
ous inﬂammatory factors but also through post-transcriptional events;
secretion of the protein, activation, endogenous inhibitors and cell sur-
face interactions [3]. De novo synthesis of large amounts MMP-9 can be
rapidly induced by cytokines, growth factors or changes in cell–cell or
cell–ECM interactions [3,49]. Like many other proteases, MMP-9 is se-
creted in the “pro” form as an inactive zymogen. Latency is conferred
by the prodomainwhichmasks the active-site cleft and prevents hydra-
tion of the catalytic zinc ion. An interaction between a sulfydryl group
on a conserved cysteine residue in the prodomain and the zinc ion con-
stitutes this “cysteine switch” [50–52]. Activation of the enzyme, there-
fore, requires either proteolytic removal of the propeptide or disruption
of the Zn2+-cysteine bond. MMP-9 is most commonly activated by
other proteases such as serine proteases, trypsin, plasmin, chymase
and other MMPs [38,48] but it can also be activated by conformational
perturbants such as heat, substrate binding, heavy metals and
organomercury compounds such as aminophenylmercuric acetate, as
well as oxidants and alkylating agents [52–56]. It has therefore been
agreed that the pro-MMP-9 has to be secreted to the ECM in order to
get activated; however other mechanisms can be also involved. Indeed,
it has been proposed that pro-MMP-9 activation could take place at the
plasmamembrane. The interactions of theMT1-MMP/MMP-2 axis with
pro-MMP-9 on the plasmamembrane induced a full activation of MMP-
9 in vitro, and under the same conditions, MMP-3 was also able to
activate MMP-9 [57]. In addition, thrombin has been shown to induce
pro-MMP-9 activation and association with β1-integrin in a human os-
teosarcoma cell line through a PI 3-kinase-dependent pathway, a key
step in thrombin-induced tumour invasion [58].
1.1.6. Endogenous inhibitors of MMPs
A large number of endogenous inhibitors ofMMPs exist, which serve
to regulate activity and prevent uncontrolled proteolysis (Table 1). Of
these inhibitors, the tissue inhibitors of metalloproteinase (TIMPs)
are the most speciﬁc for the MMPs. The TIMPs are a family of secreted
proteins which can bind all the MMPs in a 1:1 stoichiometry with
varying efﬁciencies; TIMP-1 binds toMMP-9 with high afﬁnity whereas
TIMP-2 is a more effective inhibitor of MMP-2 [59,60]. TIMPs (21 to
29 kDa) have an N- and C-terminal domain of ≈125 and 65 amino
acids, respectively, with each containing three conserved disulﬁde
bonds. The N-terminal domain folds as a separate unit and is capable
of inhibiting MMPs. The main inhibitor of MMPs in tissue ﬂuids is α2-
macrogobulin [61]. Limited proteolysis of a bait region of the plasma
protein by anMMP induces a conformational change in themacroglob-
ulin which then encloses the enzyme [62]. It is a general proteinase
inhibitor but may only bind to activatedMMPs which are then irrevers-
ible cleared by endocytosis following binding to a scavenger receptor
[63].
Other proteinswithMMP inhibiting properties, albeit less potent than
the TIMPs, include the C-terminal fragment of the procollagen C-terminal
proteinase enhancer protein (PCPE) [64]. The noncollagenous NC1
Table 1
Endogenous inhibitors of MMP-9.
Inhibitor Method of inhibition Targets Reference
TIMP-1 Catalytic activity Most MMPs, ADAM-10, ADAMTS-4 [1]
TIMP-2 Catalytic activity Most MMPs, ADAMTS-4 [1]
TIMP-3 Catalytic activity Most MMPs, ADAM-10, -12, -17, ADAMTS-4, -5 [1]
TIMP-4 Catalytic activity Most MMPs [1]
α2-macroglobulin Catalytic activity, clearance Most proteases [61]
C-terminal of PCPE Catalytic activity [64]
Tissue factor pathway inhibitor-2 Catalytic activity, activation Serine proteases, other MMPs [66]
NC1 domain of type IV collagen Catalytic activity [65]
Endostatin Catalytic activity, activation MT1-MMP [67]
TSP-1 Inhibition of activation [1]
TSP-2 Facilitates clearance [1]
RECK proteins Catalytic activity MT1-MMP [72]
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and has been shown to have MMP inhibiting properties [65]. A serine
protease inhibitor named tissue factor pathway inhibitor-2 [66],
and a collagen XVIII derived proteolytic fragment named endostatin can
block the activation of MMP-2, MMP-9 and MMP-13 as well as the cata-
lytic activity of MMP-2 and MT1-MMP [67,68]. Thrombospodin-1
(TSP-1) is an extracellular 450 kDa glycoprotein that directly binds pro-
MMP-2 and -9 and inhibits their activation [69,70]. Thrombospondin-2
(TSP-2) is thought to bind MMP-2 and MMP-9 and facilitate a low
density lipoprotein receptor-related protein (LRP)-mediated endo-
cytosis and clearance in a manner similar to α2-macroglobulin
[69,71]. Reversion-inducing cysteine-rich protein with Kazal motifs
(RECK) protein is a 110-kDa glycoprotein expressed in many normal
tissues and is the only known membrane bound MMP inhibitor
[72,73]. Finally, fatty acids have been shown to inhibit gelatinase
activity but only weakly other MMPs. Activity was dependent on
carbon chain length and presence of unsaturation, and inhibition in-
volved binding to the ﬁbronectin type II module of these gelatinases
[74]. Other excellent reviews discuss endogenous inhibitors of MMPs
in more detail [5,75].
1.2. Nitric oxide
NO is a ubiquitous gaseous and diatomic mediator, transducer and
modulator from the conversion of L-arginine to L-citrulline by nitric
oxide synthase (NOS). Three NOS isoforms have been discovered and
are classiﬁed as neuronal NOS (nNOS, NOS1), endothelial NOS (eNOS,
NOS3), which are both constitutively expressed calcium-dependent
enzymes producing physiological levels of NO, and inducible NOS
(iNOS, NOS2) which produces high levels of NO in a sustained
manner. This inducible isoform is transcriptionally upregulated in in-
ﬂammation in response to bacterial lipopolysaccharide or endotoxin,
pro-inﬂammatory cytokines and other immune complexes, some of
which also lead to the upregulation of MMP-9. The diverse roles of NO
include smooth muscle relaxation, inhibition of platelet aggregation,
neurotransmission [76], and immune and inﬂammatory modulation
[77,78]. The NO involvement in diverse physiological processes is
mostly mediated though its activation of the heme iron in the soluble
guanylate cyclase (sGC). NO can also react directly with signalling
proteins and when generated in high amounts such as during inﬂamma-
tion, it can react with superoxide anion to produce peroxynitrite, a much
stronger oxidant, with signiﬁcant pathophysiological/inﬂammatory
contributions. Although NO has a half-life in the range of seconds,
properties such as charge neutrality, a small molecular radius and hy-
drophobicity, allow for free diffusion through cell membranes. As NO
reacts with oxygen and with oxygen-derived radicals as well as metal
centres in proteins, such properties make it a key signal transducer [79].
The net effect of NO in a given setting depends on its environment
and concentration. The iNOS generates the highest local ﬂux. Following
transcriptional upregulation of the enzyme, there is a delay of 6–8 h be-
fore NO production begins but this production is then sustained forhours to days and is 1000 fold greater than those produced by the
constitutive NOS isoforms [80]. The presence of molecular oxygen and
its derived free radicals in the local environment affect NO concentra-
tion because these react at diffusion limited rates. Interestingly, vascular
relaxation and vasodilator tone caused by NO are inhibited by superox-
ide and inhibition of superoxide production may enhance the effects
of NO [81]. Therefore, scavengers of superoxide such as superoxide
dismutase and oxyhaemoglobin inﬂuence NO bioavailability.
The observed effects of NO, especially those that lead to cytotoxicity
have been also attributed to the generation of peroxynitrite from NO
and superoxide [82–87]. In addition, NO not only can react directly
with sulfhydryls [88,89], metal centres including iron/sulfur and
Zn2+-thiolate groups [82,90,91] but also can react via metal indepen-
dent mechanisms through generation of hydroxyl or carboxyl radicals
formed fromdifferent decomposition reactions [92–94]. Some excellent
reviews deal comprehensively with the chemistry and biochemistry of
NO [79,95,96].
2. Effects of NO on activation of pro-MMP-9
Inﬂammation leads to concurrent up regulation of NO and MMP-9
[97–99], however, the biological outcome of the crosstalk between
these two enzymes is not clear (see Table 2). For a detailed review of
pro-MMP-9 activation, see Fridman et al. [100]. It is also worth noting
the difﬁculties in measuring MMP-9 activity. While relative abundance
or concentration of the enzyme can bemeasured using techniques such
as western blot or ELISA, this data does not reveal the activity of the en-
zyme. Gelatin zymography is a commonly used technique which can
separate the pro and active forms of the enzyme but a recent review
has highlighted its limitations in providing true activity information
[101]. Incomplete refolding of the enzyme following electrophoresis
and dissociation of endogenous inhibitors mean that activity data can
only be obtained from gelatin zymography when it is combined with a
complimentary substrate degradation assay. Let's ﬁrst review evidence
for NO-mediated activation of MMP-9.
2.1. NO activates pro-MMP-9
NO could disrupt the Zn-thiolate bond in pro-MMP-9 leading to
its activation. For example, there is also evidence showing that NO
activates TNF-α converting enzyme, another metalloproteinase [102].
Furthermore, peroxynitrite has been shown to activate other MMPs
[83,103–105]; the free radical canmodulate the protein activity through
S-nitrosylation of cysteine thiols [106–109], and it may also release
Zn2+ from other Zn-thiolate centres [110,111].
The effect of NO on MMP-9 activation in rat retinal neurons was in-
vestigated by comparing wild-type with nNOS null animals. Increased
MMP-9 activation was observed in the wild-type rats whichwas attrib-
uted to S-nitrosylation of the pro-enzyme [112]. Co-localization of
MMP-9 activity and nNOS was also observed in the cortex. The study
went on to demonstrate that transfected recombinant MMP-9
Table 2
Reported effects of NO on MMP-9.
Cell line/strain Stimulating factor Incubation
time
NO conc. NO donor/iNOS inhibitor Observed effect Reference
nNOS−/− and wild type rats Focal cereberal ischemia and
reperfusion
NA nNOS−/− or 3-bromo-7-nitroindazole ↓MMP-9 compared to controls [55]
Puriﬁed MMP-9 0–25 h NA S-nitrosocystein ↑activation compared to controls [55]
nNOS−/− and wild type rats intravitreal injections of NMDA and
glycine
0–12 h NA nNOS−/− vs wild type rats ↓MMP-9 compared to controls [112]
Rat Brain Astrocyte cells RBA1. Endothelin-1 16 h ≈50% reduction in NO, relative to ET-1
induced levels with L-NAME 100nM
L-NAME (1, 10, 100nM) and iNOS siRNA Dose dependent reduction (up to 10
fold) in MMP 9 activity
[113]
ANA-1 macrophage INF-γ, LPS, L-arginine 4 h 50nM NO/sper ↑ at ≤50nM and ↓ at higher concs [114]
Lewis and Brown–Norway rats Allogenic (Brown Norway to Lewis)
heterotopic cardiac transplantation
24 h 1400 W (N-(3-(Aminomethyl) benzyl)
acetamidine (selective iNOS inhibitor))
↓MMP-9 activity [118]
HUVEC, NCI-H157, squamous carcinoma;
NCI-H125, adenosquamous; and NCI-
H522, adenocarcinoma
AMPA 16 h Aminoguainidine 100 μM ↑ activity following incubation with
aminoguanidine.
[124]
Puriﬁed r MMP-9 AMPA 6 h 5 or 10 nmol/min (for 0.5 and 1 μM spermin-
NONOate). 30 μM NO from 100 μM SIN-1
spermine-NONOate (0.5 and 1 μM) or
SIN-1 (20 μM, 200 μM, and 2 mM)
Dose dependent inhibition following
incubation with the NO donors.
[124]
Puriﬁed rMMP-9 0–2 h GSNO, SPER- NO, DETA NONOate,
DEA-NONOate,SNOC
DETA NONOate or Sper-NO—↓activity at
high concentration. SNOC—↑ activity
[125]
Rat glomerular mesangial cells IL-1β 36 h SNAP (up to 1mMol/L) Conc dependent ↓ inhibition (up to 90%) [175]
MDA-MB-231, MCF-7 TPA 24 h ? DETA-NO, SNAP or Spermine-NO
(500 μM)
Conc dependent inhibition. (max at
500 μM)
[177]
Rat primary astrocytes LPS 48 h Donors of 100 μM (max inhibition) SNAP or SNP ↓MMP 9 expression [176]
NHBE, HBE1, CFT1, A549 IL-1β, INF-γ, TNF-α 24 h spermine NONOate, DETA NONOate,
SIN-1, SNAP, GSNO
Dose dependent ↓with SNAP and GSNO. [178]
RA-SMCs of Sprague Dawley rats IL-1β (2 ng/ml) 24 h 2 to sixfold increase in NO. DETA NONOate (0.1–500 μM) Dose dependent ↓in MMP-9 activity and
expression
[179]
NIH/3T3 cells Thapsigargin-induced store-operated
Ca2+ entry
SNAP (200 μM) ↓in MMP-9 activity [180]
VSM from male Wistar rats IL-1β (5 ng/ml) 24 h DETA NONOate (500 μM) ↓in MMP-9 activity and expression [181]
Rat glomerular mesangial cells IL-1β (2 nmol) 48 h L-NMMA (0.3–5 mM) Conc dependent ↑ in expression and
activity.
[175]
Rat primary astrocytes LPS 48 h 7 μM of nitrite L-NAME (100 μM) ↑MMP 9 expression [176]
Rat aortic SMC IL-1β 48 h approximately 50 ng NOx/mg protein L-NMMA (50nM) 5 fold ↑ in pro MMP-9 mRNA [182]
Rat aortic smooth muscle cells from
Sprague Dawley rats
IL-1β (2 ng/ml) 48 h ↓ to 8.2 NOx (ng/mg of protein) Aminoguanidine (0–5 mM) Conc dependent. Up to 155%↑ in mRNA [183]
Rat infrarenal aorta tissue IL-1β 72 h Approximately 1250 ng/mg protein (at max
increase)
L-NMMA ↑ at ≤0.5 mM and ↓ at higher concs [184]
NHBE, HBE1 Linear scratch in the cells 24 h Approximately 14.1–389.1 μM NOx DETA NONOate (10–500 μM) ↑ expression at ≤10 μM and ↓ at higher
concs
[123]
C57BL/6 iNOS−/−. Murine neutrophils and
macrophages
Hepatic I/R injury. IL-6, or INF- γ 24 h iNOS −/−, ONO-1714 iNOS inhibition ↓MMP-9 activity. [189]
Rat aortic vascular SMC (A7r5) INF-γ, LPS, PMA 12 h L-NAME (300 μM) Inhibition to near control [190]
WiDR 8 h SNAP ↑ expression [191]
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with the NO donor S-nitrosocysteine [55]. Another group working
with rat brain astrocytes demonstrated an increase in tyrosine nitration
of theMMP-9 enzyme by co-immunoprecipitation, corresponding to an
increase in enzyme activity following iNOS induction. Inhibition of iNOS
using siRNA or L-NAME signiﬁcantly reduced nitrate accumulation and
potential MMP-9 activity as measured by gelatin zymography [113]. A
biphasic regulation of MMP-9 activity has been demonstrated in ANA-
1 cells and the trend replicated in puriﬁed pro-MMP-9 enzyme where
lower concentrations of Sper/NO result in activation of the enzyme
and higher concentrations of NO cause inhibition [114].
2.2. NO indirectly activates MMP-9
It is argued that these experiments do not provide direct evidence
for NO S-nitrosylation of the prodomain or direct activation of the
cysteine switch in vivo. During periods of prolonged inﬂammation,
where large amounts of NO are produced by iNOS, there is a
corresponding increase in oxidative species. The reaction of NO with
superoxide anion to yield peroxynitrite is key in mediating many of
the pro-oxidant and toxic effects of NO [115]. Peroxynitrite generation
could be the mechanism through which NO may indirectly activate
pro-MMP-9 as has been shown for other MMPs [83,116,117]. Inhibition
of iNOS and superoxide generation resulted in an inhibition of potential
MMP-9 activity asmeasured by zymography; however, no experiments
were carried out to ascertain whether the observed activity was as a
result of decreased protein synthesis or inhibition of protein activation
[118]. A study on term placentas of type II diabetic patients
showed that an increase in potential gelatinase B activity measured by
zymography was associated with nitration of the enzyme by
peroxynitrite [119]. Puriﬁed pro-MMP-9 was shown to be activated by
peroxynitrite and to a much greater extent by GSNO2, a product of the
reaction of glutathione and peroxynitrite. As well as increased substrate
digestion, evidence of S-glutatiolation of the pro-domain was shown
using radiolabelling and MALDI-TOF MS [120]. A rat model of reperfu-
sion injury showed that a peroxynitrite decomposition catalyst reduced
MMP-9 activation as shown by gelatin and in situ zymography [121].
Although cell surface activation of MMP-9 is likely to be less frequent,
another proposed mechanism of the indirect action of NO on MMP-9
enzyme activation is the upregulation of urokinase plasminogen
activator (uPA), which has been shown to activate pro-MMP-9 [122].
While S-nitrosocysteine caused mild activation of recombinant pro-
MMP-9, incubation of DETA NONOate with HBE1 or NHBE cell resulted
in increased uPA mRNA and therefore increased pro-MMP-9 activation
[123].
2.3. Nitric oxide-mediated inhibition of MMP-9
While the above studies provide evidence for NO activation ofMMP-
9, either directly or indirectly, there is substantial evidence for an
inhibitory role of NO on MMP-9 activity. For example, endothelial and
carcinoma co-cultures showed a marked increase in potential MMP-9
activity measured by gelatin zymography when incubated with the
iNOS inhibitor aminoguanidine. To explain the result, puriﬁed MMP-9
enzyme was incubated with NO donor spermine-NONOate and
the NO/superoxide donor SIN-1 which was expected to produce
peroxynitrite. Both incubations resulted in a signiﬁcant decrease in
enzyme activity [124]. A very interesting study in this context, suggests
that NO does not directly modulate pro MMP-9 activation. A range
of NO donors; S-nitroso-glutathione (GSNO), spermine NONO-ate
(SPERNO), DETA NONOate (DETA-NO), and DEA NONOate (DEA-NO)
and S-nitrosocysteine (CSNO) were tested on puriﬁed pro-MMP-9 en-
zyme. Of these NO donors, only SNOC caused any increase in activity.
At high concentrations, DETA-NO inhibited gelatinase activitymeasured
using a ﬂuorescent substrate. While the compounds produced different
modiﬁcations to a synthetic pro domain, these alterationswere deemedto be unrelated to enzyme activation. The NO donors were incubated
with the active form of MMP-9 and again, DETA-NO was found to
markedly inhibit enzyme activity which was unrelated to cysteine
switch activation or other oxidative modiﬁcations to the enzyme [125]
and presumably due to interactions at the active site.
While activation of pro-MMP-9 by NO seems plausible, it has not
been conclusively proven in an in-vitro or in-vivo setting. Variation in
observations may be accounted for by the use of different NO donors
with differing release properties and NO ﬂux and duration. The use of
S-nitrosocysteine as a surrogate of endogenous NO has also been
questioned [126]. The above studies show that direct activation of
pro-MMP-9 by NO is possible. The effect on MMP-9 is concentration
dependent with a trend of increased activity at low concentration and
inhibition at higher concentrations. The biological relevance of this
observation remains to be determined as the presence of other oxidants
and known MMP-9 activators are likely to be more salient in-vivo. The
actions of NO in regulation of MMP-9 distribution and expression are
expected to provide a greater net contribution to MMP-9 activity.
3. Effect of NO on MMP-9 release and distribution
Following synthesis of pro-MMP-9 enzyme, activation is dependent
on its release from the cell and availability of activating agents. Once
activated, the effect that the enzyme will exert is dependent on its
distribution at the cell surface, in the extracellular milieu or evenwithin
the cell. Its gelatinolytic activity is therefore affected by cell surface asso-
ciations, internalisation or other protein interactions. As generalised
proteolysis is seen as counterproductive for cell migration, interaction
with receptors, adhesion sites and invasive protrusions may have
developed to allow local effective concentrations of active MMP-9 and
directed ECM degradation [124,127].
Following its release, surface associated MMP-9 has been identiﬁed
in a variety of biological systems under both physiological and patholog-
ical conditions including neutrophils [128], endothelial cells [129–131],
myocardium [98,132–134], keratinocytes [135], breast epithelial
[129,136], breast cancer [137], pancreatic cancer [138], ovarian cancer
[139], prostate cancer [140], ﬁbrosarcoma [141,142], and mouse
mammary carcinoma cells [143]. It has been proposed that the afﬁnity
of the gelatinases for collagen IV, speciﬁcally through the α2 (IV)
chainmay cause the ECM to act as a reservoir for the enzymeswhich be-
come activated by inﬂammatory cells. Other interactions with CD44,
RECK and LRP proteins have been shown to cause surface localisation,
inhibition and internalisation respectively. These interactions have
demonstrated an additional, complex layer of MMP-9 regulation
which can direct the activity of the enzyme and are the subject of
other reviews [100,144]. Here we will focus on interactions that NO is
reported to inﬂuence.
Treatment of neonatal rats subjected to hyperoxia with L-NAME, an
inhibitor of NOS, led to increased activity of MMP-2 and MMP-9 in
lungs [97]. The latter effect could reﬂect the inhibitory effects of NO on
the release of these gelatinases from leukocyte gelatinase granules
[97,145], as well as from human platelets [146].
In a study investigating the effect of doxycycline on neutrophil
degranulation and MMP-9 release, nitro-glycerine (GTN) caused a
reduction in the MMP-9 activity in the cell supernatant, even though
microscopy revealed that degranulation had occurred. Most of the
MMP-9 activity was found to be associated with the cell pellet and so
it was hypothesised that nitrate caused increased cell surface associa-
tion of the enzyme [147].
Migrating trophoblasts have been shown to express MMP-9 in a
manner regulated by NO [148]. The motile cells actively redistribute
iNOS to the leading migrating edge of the cell. Interestingly, MMP-9
was found to be co-localised with iNOS at the lamellopodia and to be
crucial for cell invasion. This group postulate that the co-localisation is
either NO-mediated S-nitrosylation and activation of the pro-MMP-9
enzyme, or else a possible effect on the release or distribution of the
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MMP-9 activity establishes a further role of NO in the distribution of
active MMP-9.
The activity of MMP-9 in colon cancer cell lines is inhibited by cGMP
analogues as shown by immunoblotting and gelatin zymography. It was
discovered that this inhibition is not caused by a decrease in mRNA
levels but by a compartmental redistribution of the enzyme leading to
a tenfold increase in intracellular MMP-9 shown by ﬂow cytometry
[150].
Caveolin-1 (Cav-1) is a scaffold protein believed to play a role in sur-
vival and invasion of certain cancer types. While its exact role is poorly
understood, it seems to act as an oncogene in some cancers [151–153]
while playing the role of a tumour suppressor in others [154–157]. In
a model of hepatocellular carcinoma, overexpression of cav-1 resulted
in an increased expression of MMP-9 [158]. Conversely, a breast cancer
model shows that MMP-9 activity is reduced in cells expressing cav-1
while cell lysates showed no alteration in endogenous expression of
the enzyme. It has been suggested that cav-1 mediates an alteration in
the secretion of the gelatinase [159]. Interestingly, caveolin also plays
an important role in regulation of NOS [160]. In this context, Philips
and Birnby studied the interactions of NO with MMP-9 and cav-1
using an endothelial and lung carcinoma cell co-culture model studied
the effects of NOonMMP-9 and cav-1. Treatmentwith an iNOS inhibitor
resulted in strong co-localisation. This localisation is believed necessary
for optimum activation of MMP-9 but is abolished in the presence of an
NO donor [124].
Activation of pro-MMP-9 by other MMPs such as MMP-2, MMP-7
andMMP-13 is likely to be a cell surface event as these enzymes associ-
ate with the cell surface. One activation cascade described for MMP-9
involves the activation of plasmin from plasminogen following binding
of the urokinase plasminogen activator (uPA) to the urokinase plasmin-
ogen activator receptor (uPAR) which is on the plasma membrane.
Activated plasmin can activate pro-MMP-3 which can in turn activate
pro-MMP-9 [161]. This cascade offers the cell an opportunity to control
the distribution of activated MMP-9 and directed proteolysis. There is
evidence that NO can increase expression of uPAR but inhibit the
expression of uPA [123,162,163] and so the net effect on the distribution
of active MMP-9 is not clear.
Localisation of MMP-9 has been demonstrated to represent
another layer of regulation on its activity and NO is implicated in
this regulation. Increasing concentration of NO will increase the
internalisation or cell surface association of MMP-9 which may
occur through interaction with CD44 or collagen IV. NO can also
regulate the expression and activation of MMP-9 activating factors
including other MMPs, cav-1 and uPA which will affect the distribu-
tion of the active enzyme.
4. Effect of NO on expression of MMP-9
The MMPs, with the exception of MMP-2, are inducible enzymes
whose basal expression is low in most normal adult cells. De novo syn-
thesis of large amounts of MMPs can be rapidly induced by cytokines,
growth factors or changes in cell-cell or cell-ECM interactions [3,49].
Important inducers include tumour necrosis factor (TNF-α), interleukin
(IL-1α and β, 2, 8, 15, 17), interferon (IFN-α and γ), epidermal-growth
factor (EGF), platelet-derived growth factor (PDGF), hepatocyte growth
factor (HGF), basic ﬁbroblast growth factor (bFGF), transforming
growth factor (TGF-α andβ), amphiregulin, CCL5, bacterial lipopolysac-
charide (LPS) and phorbol esters (e.g. PMA) [48,164–166]. Physical
interactions of certain cells with the ECM or other cells that have been
shown to induceMMP expression include extracellular matrix metallo-
proteinase inducer (EMMPRIN or basigin or CD147) [167], various
integrins [168], leukocyte function-associated antigen-1 (LFA-1)
interaction with intercellular adhesion molecule-1 (ICAM-1) [169],
very late antigen 4 (VLA-4), vascular cell adhesion molecule-1
(VCAM-1) [170], gp39 and CD40 interaction [171]. Mechanical stressand alterations in cell shape have also been reported to lead to the
transcriptional upregulation of certain MMPs. The transcription of
each MMP is independently controlled depending on the cell type,
stimulating factors and therefore the signal transduction pathways
that are activated, although several MMPs share common cis-acting
elements in their promoter and are therefore co-expressed. Some
of the main pathways implicated are those involving the MAP
kinases which are composed of JNK 1/2, ERK 1/2, and p38. These
kinases may lead to the induction or inhibition of protease synthesis
depending on the cell type [172,173]. Many of these signalling
pathways converge at Jun and Fos oncoprotein activation which
heterodimerize to bind to an Activator Protein-1 (AP-1) binding
site, causing MMP upregulation [38,75]. Variation in transcription
may be accounted for by the other elements or the combination of
factors binding to the MMP promoters. ETS oncoproteins bind to
PEA3 sites [174], Nuclear Factor kappa B (NF-κB), SP-1, JAK/STAT,
and Smad are some of the contributors to MMP transcriptional
regulation [173].
Although the effects of NO on MMP-9 expression have been studied
by a number of investigators there is no agreement if NO promotes or
reduces the expression of MMP-9. The following chapters review this
conundrum as well as molecular mechanisms that may contribute to
the effects of NO.4.1. NO inhibits MMP-9 expression
Several studies report an inhibitory effect of NO donors on MMP-9
mRNA compared with stimulated controls [175–181]. Consistent with
these observations are reports that in similar cell culture models, NOS
inhibitors, which reduce NO availability, increase MMP-9 expres-
sion [175,176,182,183]. The change in mRNA appears to be dependent
on the concentration of the NOS inhibitor or NO donor used, however,
a biphasic regulation has been demonstrated where the increase in
MMP-9 expression following incubation with the NOS inhibitor
L-NMMA peaked at 0.5 mM (approximately 1250 ng NOx/mg protein).
Further increase in concentration of the inhibitor resulted in a decrease
in mRNA until it reached control levels at 5 mM (approximately
500 ngNOx/mg protein) [184]. An indirect role of NO inMMP-9 expres-
sion is through its ability to inhibit platelet aggregation [185]. This
inhibition will prevent platelet aggregate mediated increase in MMP-9
expression [186–188].4.2. NO promotes MMP-9 expression
In several studies, incubation of cells with NOS inhibitors caused an
inhibition of MMP-9 expression suggesting a promoter roll for NO
[123,189–191]. In a rat model of atherosclerosis it was reported that
MMP-9 was induced to a greater extent in iNOS+/+ rather than iNOS
−/− animals indicating that NO increases MMP-9 expression [192]. As
discussed previously, the effects of NO donors on MMP-9 expression
may also be concentration dependent, as seen with a biphasic response
to DETA-NONOate [123]. In this study, low levels of the NO donor
(10 μM) resulted in increased gene expression; however, higher
concentrations (100–500 μM) had the opposite effect. The biphasic
response may be attributed to peroxynitrite following reaction with su-
peroxide. In an ischemic–reperfusion injury model, peroxynitrite was
found to increase the expression of MMP-9, an effect that was inhibited
by NOS inhibitor L-NAME [193,194]. A study on amyloid beta degrada-
tion in Alzheimer's disease found that NO increased MMP-9 expression
both in vitro and in vivo [195]. Further evidence of the complex indirect
role of NO on MMP-9 expression was shown in a similar model where
Cav-1 inhibited MMP-9 activity. L-NAME and iNOS null mice showed
that NO decreased Cav-1 expression and so increased MMP-9 activity
[196,197].
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that modulate MMP-9 transcription
MMP-9 expression is controlled by extracellular factors which
trigger a network of signal transduction pathways resulting in transcrip-
tional upregulation. The human MMP-9 gene lies on chromosome 20
and covers 13 exons spanning 7.7 kb [198]. Expression of the gene
yields a 2.5 kb mRNA which is regulated by a 670 bp sequence within
the promoter which contains binding sites for NF-κB, AP-1, PEA3, and
SP-1 [198,199]. The complex transcriptional regulation of MMP-9 has
been the subject of intense study [200–207]. NO may preferentially
alter transcription factors that are sensitive to the cellular redox state
including NF-κB, AP-1 and SP-1 [80] (Fig. 1).
4.3.1. NF-κB
NF-κB is a transcription factor known to upregulate the transcription
of many pro-inﬂammatory mediators [208,209] and has been shown to
be essential for MMP-9 upregulation [210–212]. The interaction
between NO and NF-κB has been widely studied and previously
reviewed [213,214], however the picture remains unclear. A signiﬁcant
complicating factor in the context ofMMP-9 regulation is theNF-κB reg-
ulation of iNOS. Low concentrations of NO or presence of peroxynitrite
will augment NF-κB activity whereas at high concentration, NO is likely
to function in a negative feedback loop to reduce iNOS expression.
Reductions in NF-κB activity following exposure toNOhave been attrib-
uted to S-nitrosylation of a cysteine residue in the p50 subunit
[215,216], inhibition of NF-κB DNA binding [217] or stabilization of
IκB [218]. Increased activity has been observed at low concentration of
NO [219] through stimulation of IKK-α which likely occurs following
S-nitrosylation and activation of ras [220].
Regulation of the NF-κB pathway by NO is likely to be the same for
MMP-9 as iNOS and will depend on NO concentration and presence of
superoxide. The iNOS inhibitor aminoguanidine caused an upregulation
of MMP-9 through increased IκB degradation and NF-κB binding [183].proMMP-9 M
sGC
cGMP
PKG
Ras
Raf
MEK1/2
PKC
ERK1/2
Growth factors
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Fig. 1. Representation of some of the pathways involved in the transcriptional upregulation
concentration and ↓ indicates low concentration. + indicates a promoter role and− indicates a
of peroxynitrite. TNF-α, tumour necrosis factor-alpha; IL-1, interleukin-1 (alpha or beta); IκB,
activated protein kinase kinase kinase (MAPKKK)-family]; MAPK, mitogen-activated protei
MAPKK kinase; MEK/MKK, MAPK/ERK kinase; MEKK, MEK kinase; ERK, extracellular signal-re
soluble guanylate cyclase; cGMP, cyclic guanosine monophosphate; PKC/PKG, protein kinase CS-nitrosothiols inhibited p50 nuclear translocation and NF-κB DNA
binding, thus reducing TNF-α mediated MMP-9 expression [178].
Superoxide and peroxynitrite have an opposite role to NO and increase
p65 nuclear translocation and NF-κB binding [210,221]. Reactive
oxygen species (ROS) generated from NADPH oxidase also activated
NF-κB resulting in an upregulation of MMP-9 [222]. The effects on
MMP-9 expression are, however, cell speciﬁc and NF-κB has been
reported to play no role in some cases [177,223].
4.3.2. AP-1
AP-1 consists of a mixture of dimeric basic region-leucine zipper pro-
teins (bZIP) that belong to the Jun, Fos, Maf and ATF sub families. C-Jun is
the most potent transcriptional activator whereas Fos proteins cannot
homodimerise but form heterodimers with Jun proteins [224]. The AP-1
motif in theMMP-9 gene is considered by some to be themost important
for its expression [201,211]. Indeed, a singlemutation in the AP-1 binding
site abolishes TNF-α or IL-1β induced MMP-9 expression [210,225]. NO
can modulate AP-1 activity through modiﬁcations of a redox sensitive
cysteine residue in c-Jun or c-Fos [226]. Oxidation or nitrosylation reduces
DNA binding [227].
DETA-NO is reported to inhibit the MMP-9 transcriptional upregula-
tion in response to TPA in breast cancer cells. This effectwas attributed to
inhibition of c-Jun using EMSA and TransAM assay [177]. NOS inhibitors
increase AP-1 binding by approximately 200% compared with IL-1β
stimulated cells [183]. Where NO caused the upregulation of MMP-9,
AP-1 was shown to be critical by using AP-1 deletion mutants of MMP-
9 luciferase promoter constructs [191]. Superoxide has been shown to
increase AP-1 binding in MMP-9 upregulation [210].
4.3.3. cGMP/protein kinase G
Many of NO's diverse physiological actions are attributed to its
ability to activate soluble guanylate cyclase (sGC) through binding of
its heme group. Activation of sGC triggers formation of cyclic GMP, an
important signalling molecule [80]. cGMP exerts its effects throughMP-9
AP-1
p50/p65cJun/cFos
IL-1
Rac/Cdc42
MEKK 1-3
JNK 1/2
P50/p65
p38
MKK3/6
O-
ONOO-
of MMP-9 and the possible impacts of NO and peroxynitrite (ONOO−). ↑ indicates high
n inhibitory role. The effect exerted by NOwill depend on the concentration and presence
inhibitor of NF-κB; IKK (α or β), IκB (α or β) kinase; MEKK1-6, MEK1-6 kinase [mitogen-
n kinase; MAPKAPK, MAPK-activated protein kinase; MAPKK, MAPK kinase; MAPKKK,
gulated kinase; JNK/SAPK, c-jun N-terminal kinase/stress-activated protein kinase; sGC,
/G; NF-κB, nuclear factor-kappa B; AP-1, activating protein-1.
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(PKA) and protein kinase G (PKG) [228], where change is effected
through transcription factor phosphorylation and/or transcription.
Interestingly, transcription factors, including AP-1, that are activated
by cGMP are also regulated by NO through protein modiﬁcation
[229]. Several conﬂicting studies have used speciﬁc inhibitors of sCG,
analogues of cGMP or PKG to determine whether observed effects of
NO on MMP-9 expression are mediated through this pathway.
cGMP analogues canmimic theNOdonormediated down regulation
of MMP-9 in MCF-7 cells. This down regulation was blocked following
co-incubationwith a PKG inhibitor, implicating the cGMP/PKG pathway
[177]. Similar results were reported in smooth muscle cells where
inhibition of MMP-9 activity by eNOS gene transfer was mimicked by
DETA-NONOate or the cGMP analogue 8-bromo-cGMP [230].
Where MMP-9 expression was potentiated by NO, the addition of a
sGC inhibitor returned MMP-9 mRNA to basal levels [191]. Similar
results were reported when NO-donor mediated upregulation of
MMP-9 was inhibited following co-incubation with sGC or PKG inhibi-
tors. The role of the pathway was conﬁrmed when the addition of a
cGMP analogue reversed the effect [190].
Where a biphasic regulation of MMP-9 was observed, the stimula-
tion observed at low NO level were attributed to cGMP, whereas
the inhibition observed at higher concentrations was independent of
sGC/cGMP [114]. In another study where MMP-9 was upregulated by
NO, activation of a sGC/PKA pathway resulted in phosphorylation of
Wilms tumour 1 (WT1). Phosphorylation caused a shuttling of WT1, a
transcriptional repressor, from the nucleus to the cytosol causing
upregulation of MMP-9 [231]. The NO sensitive cGMP/PKG pathway
also negatively regulates store-operated Calcium entry (SOC) in ﬁbro-
blasts. This inhibition has been reported to indirectly inhibit MMP-9
synthesis and release, where increased SOC increases MMP-9 release
[180].
The inﬂuence of cGMP is likely cell speciﬁc, as NO-donor mediated
inhibition of MMP-9was found to be independent of cGMP in endothe-
lial cells [223] and cGMP analogues were unable to replicate the
effects of NO in IL-1β stimulated rat mesangial cells [175]. It is reported
elsewhere that PKG had no effect on basal or NO modulated MMP-9
expression [123]. This suggests a PKG independent cGMP mediated
pathway.4.3.4. MAP kinases/protein kinase C
The mitogen activated protein kinases (MAPK) [232] and protein
kinase C (PKC) [200] are two families of kinase signalling cascades
involved in the activation of MMP-9 transcription factors. AP-1 and
NF-κB are both regulated byMAP kinaseswhich can in turn be activated
by PKC-ζ, so interactions between the molecules in MMP-9 regulation
seem likely [200].
Protein kinase C is a family of isoenzymes with differential distribu-
tion, substrate speciﬁcities and activation responsiveness. They are
split into conventional (α, βI, βII, γ), novel (δ, ε, η/L, θ) and atypical
(ζ, λ/L). Few studies have examined the speciﬁc isoenzyme involved
in MMP-9 expression but PKC-α, β, and in particular ζ have been
implicated [200,201]. NO donors have been shown to inhibit JNK
through S-nitrosylation in several cell models [233–236]. Inhibitors of
p38 and ERK MAP kinases showed an additive reduction though not
complete inhibition of IL-1β or superoxide stimulated MMP-9 mRNA.
Superoxide worked with IL-1β to increase phosphorylation of ERK,
p38 and JNK to increase MMP-9 expression [210].
In one study where AP-1 was inhibited by an NO donor, the up-
stream MAPK, JNK was unaffected. The donor caused an inhibition of
PKC-δ resulting in reducedMMP-9 expression [177]. ERK1/2 stimulated
by LPSwas also shown to be inhibited by anNO donor. Interestingly, the
inhibition was reversed with a cGMP analogue [176]. DETA-NONOate
was found to attenuate superoxide mediated ERK activation and
MMP-9 upregulation in vascular smooth muscle cells [181].In a colon cancer cell line, NO caused the upregulation of MMP-9.
The upregulation was abolished in the presence of inhibitors of sGC,
PKG or ERK. The study showed that NO caused the upregulation in a
cGMP/PKG/ERKdependentmanner and can increase ERK 1/2 phosphor-
ylation by 12 fold [191].
A careful analysis of reports onNO-stimulator or NO-inhibitor effects
on the MMP-9 gene expression allows for the following conclusions.
First, as MMP-9 is an inducible enzyme and basal expression levels are
often low, the stimulating factor can strongly affect response. Nitric
oxide does not appear to inﬂuence basal MMP-9 expression [175,177].
Second, reports describing opposing effects of NO on gene expression
may be explained by the complexity of the regulation and the inﬂuence
of cell type, NO source (physiological, pathological or pharmacological),
its concentrations and duration of action, as well as timing of exposure
of MMP-9-generating systems to NO.
5. Nitric oxide and its effects on MMP-9 mRNA stability
Post-transcriptional regulation is increasingly recognised as being
critical for gene expression. Microarray studies have shown that over
half of stress-response genes are regulated by changes inmRNA stability
[237,238]. Regulation of the fate ofmRNA is through its 3′UTR (untrans-
lated region) which contain cis-regulatory elements. The adenylate and
uridylate-rich elements (AREs) constitute one class of these elements
that regulate cytoplasmic mRNA [239] and target labile mRNA for
degradation [240]. Several families of ARE-binding proteins (ARE-BP)
regulate the fate of the mRNA. HuR is a ubiquitously expressed ARE-
BP belonging to the ELAV family which stabilizes ARE containing
mRNAs [241,242]. NO has been shown to regulate the expression of sev-
eral genes including heme oxygenase 1 [243], transforming growth
factor-β3 [244], endothelin-converting-enzyme-1 [245], IL-8, TNF-α
and p21/Waf1 [246] by inﬂuencing the mRNA stability. Interestingly,
binding of HuR is found to be essential for the stability of iNOS mRNA
[247] and the inhibition of sGC induced by cAMP results from inhibition
of HuR expression [248]. It has also been shown elsewhere that cGMP-
elevating agents decrease the expression and RNAbinding of HuR [249].
MMP-9 mRNA contains numerous AUUAmotifs in its 3′UTR and the
stabilizing effects of HuR have been reported [250,251]. The stability of
existing mRNA can be measured using actinomycin to block de novo
synthesis of mRNA. Nitric oxide donors were shown to inhibit the
expression of HuR and thus reduce its binding to in the 3′UTR through
a sGC-cGMP pathway [252]. The half-life of MMP-9 mRNA from rat
mesangial cells was reduced from 8 h to 4 h following co-incubation
with NO-donors [253]. This ﬁnding was consistent with the discovery
that the stability of the MMP-9 mRNA is dependent on HuR binding to
the ARE.
Where DETA-NONOate reduced the stability ofMMP-9mRNA in cul-
tured astrocytes, AUF-1, and not HuR, was found to play a mediating
role. Protein levels of the mRNA destabilising factor and its binding to
theMMP-9 3′ UTR were found to be increased following addition of
the NO donor [254]. Addition of AUF-1 siRNA was found to partially
reverse the NO mediated inhibition of MMP-9 and thus conﬁrming a
further mechanism of NO mediated MMP-9 mRNA destabilisaiton.
Based on the available evidence,we conclude that increased concen-
trations of NO reduce the stability ofMMP-9mRNA,most likely, through
downregulation of HuR and increased expression of AUF-1.
6. NO and MMP-9 in the tumour microenvironment
Our current understanding of the role of MMP-9 in cancer is incom-
plete but has been summarised elsewhere [1,5,38] and is seen as being a
key agonist in the progression of several cancers including colorectal,
lung, oral and pancreatic through increasing invasion, metastasis and
angiogenesis [24,255]. While upregulation of MMPs by tumours has
long been established, it is now known that stromal cells, such as ﬁbro-
blasts, endothelial cells and leucocytes can play an equally important
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activation of growth factors in the ECM by tumour cells, release of
cytokines and growth factors, and through direct cell–cell contact with
tumours [256,257]. Tumours and tumour associated stromal cell inter-
actions are incompletely understood, but their recruitment serves to en-
hance the metastatic efﬁciency. An interesting study on skin squamous
cell carcinoma found that increased expression of stroma-dervied
MMP-9 occurred exclusively in enhancedmalignant tumour transplants
[258]. NO is believed to play a dual role in metastasis which may be
linked to its concentration within the tumour microenvironment
[259], where sources of NO include macrophages, neutrophils, ﬁbro-
blasts, endothelial cells and in some cases, tumours themselves and
all three NOS isoforms have been implicated in various cancer types
[259]. An interesting study on themechanism of IL-2/α-CD40 immuno-
therapy found that the inhibition of metastasis was as a result of induc-
tion of iNOS expression by stromal macrophages and therefore a
reduction in MMP-9 expression and activity within the tumour. An NO
donor JS-K was able to mimic these effects [260]. To our knowledge,
this is the ﬁrst example of an NO mediated cross-talk between the
tumour and stroma resulting in the regulation of MMP-9 but it would
seem likely to be more ubiquitous given the prevalence of NO and
MMP-9 upregulation.7. Using NO donors/mimetics as therapeutic agents
The quest for a clinically useful MMP inhibitor (MMPi) has been on-
going for several decades. The most common problems encountered
during clinical development such as poor efﬁcacy and side effects have
been attributed to inadequate MMP subtype speciﬁcity. Over the past
number of years, our knowledge of the role of individual MMPs in
various processes and the regulation of these enzymes has greatly
expanded. However, the emerging network and relationship between
MMPs and their physiological and pathophysiological environments
appear to be more complex than it had been originally anticipated.
Therefore, the real challenge may not lie merely in the development of
selective inhibitors of anMMP subtype (whichmight have multiple op-
posing roles in vivo), but rather in regulating the dysregulated enzymes
activity that is speciﬁcally associated with pathobiology. This complex
problem may require us to look at factors controlling MMP expression
and aberrant activity. As more is being understood about the role of en-
dogenous NO in various disease processes and more studies are being
conducted on the inﬂuence of NO on MMP-9 regulation, nitrates and
other NO donors may prove useful as therapeutic agents in inhibition
of dysregulated MMPs.
NO has been incorporated into several established pharmacological
agents as NO-drug hybrids in an effort to enhance efﬁcacy and decrease
side-effects of the resultant pharmacological agents. Of these, hybrids
of NO with non-steroidal anti-inﬂammatory drugs (NO-NSAIDS)
[261–264], NO-glucocorticoids [265–267], and NO-salbutamol
[268–270] have been extensively studied for their anti-inﬂammatory
properties but not speciﬁcally as MMP-9 inhibitors.
Glyceryl trinitrate (GTN) has long been used clinically for over
150 years and has a well-established toxicity proﬁle [271]. Its potential
use as an MMPi was demonstrated when it reduced plasma MMP-9
levels by increasing the enzyme membrane binding and inhibited
release [147]. In contrast, GTN is reported to activate pro-MMP-9
[272], increasing potential MMP-9 activity through an increase in NF-
κB activation [273] and increased MMP-9 expression [274].
Our group has reported an interesting family of barbiturate–nitrate
hybrids. These compounds are able to inhibit MMP-9 catalytic activity
and reduce MMP-9 secretion. The hybrids more potently inhibited
tumour cell invasion than their non-nitrate analogues [275]. These
promising results illustrate the potential for the use of NO donors or
nitrate-hybrids in the treatment of conditions where MMP-9 plays a
role in the pathophysiology.Many of the issues relating to the use of NO donors asMMP-9 inhib-
itors overlap with their use as anti-cancer agents and are already the
subject of review [276]. Understanding the endogenous role of NO in a
given disease state, in particular the concentration threshold for any
dual response, will be key in the effective use of these compounds as
therapeutic agents.
8. Conclusion
The role of NO in the regulation of MMP-9 has been the subject of
intense study over the previous two decades and the models used
have spanned several cell types and disease states. This review
presents these studies and the often conﬂicting results as a represen-
tation of the dual nature of the molecule at almost every level of
MMP-9 regulation. In making sense of the apparent contradiction
in the results, it is crucial to ﬁrst understand the role of concentra-
tion in this biphasic nature of NO. NO effects are often separated
into cGMP dependent, which tend to occur at lower NO ﬂux, and
cGMP independent, occurring at higher concentrations. These
cGMP independent effects are often mediated by formation of
peroxynitrite [86,87,277,278], leading to direct reaction with
proteins to alter their function through S-nitrosylation, tyrosine
nitration or oxidisation [279]. Indeed, peroxynitrite often opposes
the biological effects of NO [86,87,280–282]. The balance of these
reactions will often give rise to a threshold in concentration, beyond
which the role of NO may change. To further complicate this
concentration-dependent role of NO, effects will also be cell- and
environment-speciﬁc depending on the presence of endogenous
antioxidants [283] and other genes involved in regulating a given
response. The dichotomy of protective and damaging effects of NO
is evident in inﬂammation, where iNOS is generally considered
pro-inﬂammatory, whereas eNOS and nNOS are considered anti-
inﬂammatory [284] and also in the dual roles of NO in apoptosis
[277,285].
Through studies with recombinant pro-MMP-9, activation of the
zymogen by NO donors has been demonstrated. Other studies have
shown that this effect is dependent on the donor used and that higher
concentrations of NO may in fact inhibit enzyme activity through
interaction with the active site. The overall relevance of these ﬁndings
in an in-vivo setting remains to be determined. NO also directs proteol-
ysis by MMP-9 by affecting local activity through increased cell surface
association, directed distribution, internalisation or modulation of pro-
MMP-9 activating factors. Regulation of MMP-9 expression by NO is a
concentration dependent event with a trend of increased expression
at low NO concentration and downregulation at higher concentrations
of NO. This trend may not hold for all cells and will depend on the
stimulating factors and so, the transcription factors involved in the
expression. Activity of NF-κB and cGMP are both increased at low NO
and inhibited at high NO concentration and so follow this observed
trend. Increasing levels of NO will also reduce MMP-9 expression
through a decrease in mRNA stability.
Despite intense work in the ﬁeld over previous decades, and
increased understanding of the role of MMP-9 in human pathology,
clinically useful MMP inhibitors have proven elusive. This review high-
lights the complexity of NO-MMP-9 interactions and presents some of
the challenges that have been encountered and need to be resolved.
Further studies to separate the opposing roles of NO in MMP-9 regula-
tion will clarify its part in a given disease process and will allow its
inhibitory role to be exploited as a therapeutic agent.
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